ERBB2 and breast cancer: Although it is yet to be clinically investigated, Gadan and colleagues have proposed the use of BNCT to treat locoregional recurrences in HER2+ breast cancers using immunoliposomes labeled with the monoclonal antibody, Trastuzumab.